The pScreen Card
THE CREDIT CARD SIZED, DISPOSABLE, SINGLE USE, READER-FREE ASSAY FOR THE QUANTIFICATION OF PROTEIN AND BIOMARKERS IN TINY SAMPLE VOLUME.
Complex Diagnoses Made Simple
ACCURATE, EASY TO USE, ACCESSIBLE ANYTIME, ANYWHERE YOU GO
Our pScreen™ device only requires two drops of blood (or urine). The highly sensitive immunoassay detects and quantifies biomarkers within 15 minutes. It provides results that are comparable in accuracy to the ELISA and other laboratory-performed tests. Severe and chronic illnesses can be identified and monitored quickly and efficiently.
pScreen Unique Features
- No sample preparation
- Requires only two droplet of body fluid
- No electricity or battery power needed
- Fully disposable, as compact as a credit card
- Accurate and sensitive biomarker readings
- Results are ready in less than 20 minutes
The pScreen™ test stands apart from both laboratory tests and other point-of-care tests when it comes to convenience and cost. Everything needed to perform the test is inexpensive and disposable. Now, diagnostic tests can be performed anywhere: private practices, hospital rooms, clinics, in homes or out in the field. Patients with chronic illnesses can monitor their condition in the comfort of their own homes.
The pSCREEN Card Is All About Saving:
Time. Money. Recourses.
When it is time to test, anywhere you are, simply apply a small drop of body fluid (e.g., finger prick blood, urine) onto the pScreen™. In less than 20 minutes, pScreen™ allows you to monitor and track the level of proteins (biomarkers) that map your health risk.
How the pSCREEN Card Works?
Read test result directly on the pScreen's test scale - it is as easy as reading a thermometer - or simply scan the pScreen™ card with your smartphone to store and share the results to your healthcare provider. No more lines, no more waiting. Simple. Safely dispose the single use card, and you are done. When needed, use a second individually wrapped pScreen™.
The pScreen technology is the result of two years of intense experimental and computational research conducted by Drs. A. Gandini and J. Antaki at the Biomedical Engineering Department, at Carnegie Mellon University. The technology was licensed to Accel Diagnostics who invested three additional years of development to perfect it and complete numerous validation tests.